Trials / Completed
CompletedNCT00152009
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 345 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPD503 (Guanfacine hydrochloride) (2 mg) | |
| DRUG | SPD503 (3 mg) | |
| DRUG | SPD503 (4 mg) | |
| DRUG | Placebo |
Timeline
- Start date
- 2003-01-29
- Primary completion
- 2003-08-23
- Completion
- 2003-08-23
- First posted
- 2005-09-09
- Last updated
- 2021-06-10
- Results posted
- 2009-11-26
Source: ClinicalTrials.gov record NCT00152009. Inclusion in this directory is not an endorsement.